Cloning strategies using a third irrelevant enzyme site (TIES) to overcome certain cloning problems

We describe a cloning strategy, third irrelevant enzyme site (TIES), based on three-component assembly ligation reactions to overcome seven types of problematical cloning reactions. Implementation of the TIES strategy has made it possible to obtain the desired recombinant where the corresponding app...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:BioTechniques. - 1993. - 20(1996), 1 vom: 05. Jan., Seite 68-72, 74, 76 passim
1. Verfasser: Zeng, M (VerfasserIn)
Weitere Verfasser: Huang, B R, Lapeyre, J N
Format: Aufsatz
Sprache:English
Veröffentlicht: 1996
Zugriff auf das übergeordnete Werk:BioTechniques
Schlagworte:Comparative Study Research Support, U.S. Gov't, P.H.S. Technical Report Journal Article DNA, Recombinant DNA Restriction Enzymes EC 3.1.21.-
LEADER 01000caa a22002652 4500
001 NLM087420678
003 DE-627
005 20250130164320.0
007 tu
008 231222s1996 xx ||||| 00| ||eng c
028 5 2 |a pubmed25n0292.xml 
035 |a (DE-627)NLM087420678 
035 |a (NLM)8770409 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Zeng, M  |e verfasserin  |4 aut 
245 1 0 |a Cloning strategies using a third irrelevant enzyme site (TIES) to overcome certain cloning problems 
264 1 |c 1996 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 25.10.1996 
500 |a Date Revised 28.09.2018 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a We describe a cloning strategy, third irrelevant enzyme site (TIES), based on three-component assembly ligation reactions to overcome seven types of problematical cloning reactions. Implementation of the TIES strategy has made it possible to obtain the desired recombinant where the corresponding approach using conventional recombinant DNA methodologies and two-component ligations failed to give the desired product 
650 4 |a Comparative Study 
650 4 |a Research Support, U.S. Gov't, P.H.S. 
650 4 |a Technical Report 
650 4 |a Journal Article 
650 7 |a DNA, Recombinant  |2 NLM 
650 7 |a DNA Restriction Enzymes  |2 NLM 
650 7 |a EC 3.1.21.-  |2 NLM 
700 1 |a Huang, B R  |e verfasserin  |4 aut 
700 1 |a Lapeyre, J N  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t BioTechniques  |d 1993  |g 20(1996), 1 vom: 05. Jan., Seite 68-72, 74, 76 passim  |w (DE-627)NLM012627046  |x 0736-6205  |7 nnns 
773 1 8 |g volume:20  |g year:1996  |g number:1  |g day:05  |g month:01  |g pages:68-72, 74, 76 passim 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_21 
912 |a GBV_ILN_22 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_60 
912 |a GBV_ILN_62 
912 |a GBV_ILN_65 
912 |a GBV_ILN_70 
912 |a GBV_ILN_99 
912 |a GBV_ILN_121 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_350 
912 |a GBV_ILN_618 
912 |a GBV_ILN_640 
912 |a GBV_ILN_754 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2002 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2007 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2009 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2015 
912 |a GBV_ILN_2018 
912 |a GBV_ILN_2023 
912 |a GBV_ILN_2035 
912 |a GBV_ILN_2040 
912 |a GBV_ILN_2060 
912 |a GBV_ILN_2099 
912 |a GBV_ILN_2105 
912 |a GBV_ILN_2121 
912 |a GBV_ILN_2470 
951 |a AR 
952 |d 20  |j 1996  |e 1  |b 05  |c 01  |h 68-72, 74, 76 passim